Cardiovascular outcome evidence in diabetes and metabolism, including MACE, heart failure, renal outcomes, lipid therapy, hypertension, and cardiometabolic risk reduction.
An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.
An open-label randomized trial in newly diagnosed type 2 diabetes found acarbose and vildagliptin both lowered plasma TMAO, with a greater fall on acarbose. PICO summary and expert commentary.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.
A pooled analysis of three finerenone trials found a modest reduction in new-onset atrial fibrillation/flutter across the cardio-kidney-metabolic spectrum. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
A small randomized trial compared perindopril plus indapamide against perindopril plus moxonidine (both with metformin) for left ventricular and renal protection in hypertension with prediabetes. PICO summary and expert commentary.
A secondary analysis of the CORDIOPREV trial reports that a lower baseline neutrophil count is associated with type 2 diabetes remission in patients with coronary heart disease following a Mediterranean diet. PICO summary and expert commentary.
A post-hoc pooled analysis of four randomised trials found once-weekly semaglutide lowered the composite of cardiovascular death or worsening heart failure events in patients with HFpEF, with no significant effect on cardiovascular death alone. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
